Saltar al contenido
Merck

H102

Supelco

Haloperidol metabolite II

analytical standard

Sinónimos:

(±)-4-(4-Chlorophenyl)-α-(4-fluorophenyl)-4-hydroxy-1-piperidinebutanol, Reduced Haloperidol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C21H25ClFNO2
Número de CAS:
Peso molecular:
377.88
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24

grado

analytical standard

Nivel de calidad

Ensayo

≥98% (HPLC)

Formulario

solid

técnicas

HPLC: suitable
gas chromatography (GC): suitable

color

white

solubilidad

DMSO: 10 mg/mL

aplicaciones

forensics and toxicology
pharmaceutical (small molecule)
veterinary

Formato

neat

cadena SMILES

OC(CCCN1CCC(O)(CC1)c2ccc(Cl)cc2)c3ccc(F)cc3

InChI

1S/C21H25ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,20,25-26H,1-2,11-15H2

Clave InChI

WNZBBTJFOIOEMP-UHFFFAOYSA-N

Aplicación

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type N95 (US)


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Naoya Kishikawa et al.
Analytical and bioanalytical chemistry, 386(3), 719-724 (2006-09-08)
A simultaneous method for the determination of haloperidol (HP) and its metabolite, reduced haloperidol (RHP), in human serum was developed by means of high-performance liquid chromatography (HPLC) with fluorescence detection. Suzuki coupling reaction with a fluorescent arylboronic acid, 4-(4,5-diphenyl-1H-imidazol-2-yl)phenylboronic acid
D W Eyles et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 8(2), 127-129 (1998-06-10)
In vitro, cytosolic human ketone reductases catalyse the stereospecific (i.e. >99%) formation of S(-) reduced haloperidol (RHP) from haloperidol (HP). Whether this situation is reflected in patients taking the drug is unknown. In this study in nine patients taking HP
L Pan et al.
European journal of clinical pharmacology, 55(8), 599-604 (1999-12-14)
To investigate in vitro which CYP isoforms (CYP1A2, CYP2D6 and CYP3A4) are involved in the biotransformation of haloperidol (HAL) and reduced haloperidol (RHAL). The biotransformation of HAL and RHAL is evaluated by measuring HAL and RHAL remaining after incubation with
D W Eyles et al.
Psychopharmacology, 116(2), 161-166 (1994-10-01)
In patients taking haloperidol (HP), circulating concentrations of reduced haloperidol (RHP increase disproportionately to the dose or concentration of the parent drug. In the current study, we tested the hypothesis that the nonlinearity is due to preferential saturation of the
W H Chang et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 4(2), 119-126 (1994-06-01)
Plasma haloperidol (HL) and reduced haloperidol (RH) levels were measured in 60 schizophrenic patients treated with high to very high HL doses of 40-200 mg/day. Plasma samples were obtained at steady-state conditions and 10-12 h after the evening dose and

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico